Guizhou Baixiang Pharmaceutical

Guizhou Baixiang Pharmaceutical is a specialized pharmaceutical company headquartered in Guiyang, China, primarily focused on the production of Traditional Chinese Medicine (TCM) and modern therapeutic agents. The company is a significant player in the Chinese oncology market, most notably for its proprietary Compound Cantharidin Capsules used in the treatment of liver, lung, and digestive tract cancers. In 2014, the company was acquired by the publicly traded Guizhou Yibai Pharmaceutical for 612 million RMB to consolidate Yibai's leadership in the anti-tumor drug sector. Beyond oncology, Baixiang manufactures a variety of treatments for gynecological disorders and cardiovascular conditions. The company maintains large-scale, GMP-compliant manufacturing facilities and leverages regional herbal resources for its product development.